Protective effects of silymarin against doxorubicin-induced toxicity

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2697-2704

  Cecen, E ^a   Dost, T ^a   Culhaci, N ^a   Karul, A ^a   Ergur, B ^b   Birincioglu, M ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Cancer; Doxorubicin; Milk thistle; Silibinin; Silybum marianum; Silymarin; Toxicity

Indexed keywords

EID: 84858192412     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007). Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother, 8, 1039-58.
2. Bertani T, Poggi A, Pozzoni R et al (1982). Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest, 46, 16-23.
3. Bokemeyer C, Fels LM, Dunn T et al (1996). Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer, 74, 2036-41.
4. Boonsanit D, Kanchanapangka S, Buranakarl C (2006). L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology, 11, 313-20.
5. Chen A, Sheu LF, Ho YS et al (1998). Experimental focal segmental glomerulosclerosis in mice. Nephron, 78, 440-52.
6. Cheung CW, Gibbons N, Johnson DW, Nicol DL (2010). Silibinin-a promising new treatment for cancer. Anticancer Agents Med Chem, 10, 186-95.
7. Comelli MC, Mengs U, Schneider C, Prosdocimi M (2007). Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther, 6, 120-9.
8. Deman A, Ceyssens B, Pauwels M et al (2001). Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrol Dial Transplant, 16, 147-50.
9. Doroshow JH, Locker GY, Myers CE (1980). Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest, 65, 128-35.
10. El-Shitany NA, El-Haggar S, El-desoky K (2008). Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol, 46, 2422-8.
11. Gaedeke J, Fels LM, Bokemeyer C et al. (1996). Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant, 11, 55-62.
12. Ganey PE, Kauffman FC, Thurman RG (1988). Oxygen-dependent hepatotoxicity due to doxorubicin: role of reducing equivalent supply in perfused rat liver. Mol Pharmacol, 34, 695-701.
13. Gatta G, Capocaccia R, Coleman MP, Ries LA, Berrino F (2002). Childhood cancer survival in Europe and the United States. Cancer, 95, 1767-72.
14. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE (1998). Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol, 27, 53-68.
15. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol, 25, 72-85.
16. Injac R, Perse M, Cerne M et al (2009). Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials, 30, 1184-96.
17. Jeyaseelan R, Poizat C, Wu HY, Kedes L (1997). Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem, 272, 5828-32.
18. Kalender Y, Yel M, Kalender S (2005). Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology, 209, 39-45.
19. Karimi G, Ramezani M, Tahoonian Z (2005). Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med, 2, 383-6.
20. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H (1990). Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther, 47, 219-31.
21. Krischer JP, Epstein S, Cuthbertson DD et al (1997). Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol, 15, 1544-52.
22. Kroll DJ, Shaw HS, Oberlies NH (2007). Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther, 6, 110-9.
23. Ladas EJ, Kroll DJ, Oberlies NH et al. (2010). A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer, 116, 506-13.
24. Li L, Gao Y, Zhang L et al (2008). Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett, 272, 61-9.
25. Li L, Zeng J, Gao Y, He D (2010). Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs, 19, 243-55.
26. Lipshultz SE, Colan SD, Gelber RD et al (1991). Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med, 324, 808-15.
27. Lipshultz SE, Lipsitz SR, Mone SM et al (1995). Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med, 332, 1738-43.
28. Lipshultz SE, Lipsitz SR, Sallan SE et al. (2005). Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol, 23, 2629-36.
29. Liu LL, Li QX, Xia L, Li J, Shao L (2007). Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology, 231, 81-90.
30. Liu Y, Thurman RG (1992). Potentiation of adriamycin toxicity by ethanol in perfused rat liver. J Pharmacol Exp Ther, 263, 651-6.
31. Mansour HH, Hafez HF, Fahmy NM (2006). Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats. J Biochem Mol Biol, 39, 656-61.
32. Myers C (1998). The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol, 25, 10-4.
33. Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J (1998). Semiautomated measurement of nitrate in biological fluids. Clin Chem, 44, 679-81.
34. Ohkawa H, Ohishi N, Yagi K (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 95, 351-8.
35. Olson RD, Mushlin PS (1990). Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J, 4, 3076-86.
36. Paglia DE, Valentine WN (1967). Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med, 70, 158-69.
37. Patel N, Joseph C, Corcoran GB, Ray SD (2010). Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol Appl Pharmacol, 245, 143-52.
38. Post-White J, Ladas EJ, Kelly KM (2007). Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther, 6, 104-9.
39. Pritsos CA, Ma J (2000). Basal and drug-induced antioxidant enzyme activities correlate with age-dependent doxorubicin oxidative toxicity. Chem Biol Interact, 127, 1-11.
40. Psotova J, Chlopcikova S, Grambal F, Simanek V, Ulrichova J (2002). Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res, 16, S63-7.
41. Ramasamy K, Agarwal R (2008). Multitargeted therapy of cancer by silymarin. Cancer Lett, 269, 352-62.
42. Rhoden EL, Lucas ML, Pereira-Lima L, Rhoden CR, Souto CA (2001). Effects of L-arginine on the kidney levels of malondialdehyde in rats submitted to renal ischaemia-reperfusion. BJU Int, 88, 273-7.
43. Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM (2001). Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol, 89, 140-4.
44. Sun Y, Oberley LW, Li Y (1988). A simple method for clinical assay of superoxide dismutase. Clin Chem, 34, 497-500.
45. Tietze F (1969). Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem, 27, 502-22.
46. Wink DA, Cook JA, Christodoulou D et al (1997). Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide, 1, 88-94.
47. Yagmurca M, Bas O, Mollaoglu H et al (2007). Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res, 38, 380-5.
48. Yagmurca M, Erdogan H, Iraz M et al (2004). Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats. Clin Chim Acta, 348, 27-34.
49. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S (2006). Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology, 218, 164-71.